{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T11:11:55Z","timestamp":1782040315191,"version":"3.54.5"},"reference-count":53,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Protein kinase C (PKC) is a family of protein kinase enzymes that can phosphorylate\nother proteins and influence their functions, such as signal transduction, cell survival, and death. Increased\ndiacylglycerol (DAG) concentrations, which are typically observed raised in hyperglycemic\nsituations such as diabetes mellitus, can also activate PKC enzymes (DM). On the other\nhand, PKC isomers have been shown to play an essential role in diabetes and many hyperglycemic\ncomplications, most importantly atherosclerosis and diabetic cardiomyopathy (DCM). As a result,\nblocking PKC activation via DAG can prevent hyperglycemia and related consequences, such as\nDCM. Wogonin is a herbal medicine which has anti-inflammatory properties, and investigations\nshow that it scavenge oxidative radicals, attenuate nuclear factor-kappa B (NF-\u03baB) activity, inhibit\nseveral essential cell cycle regulatory genes, block nitric oxide (NO) and suppress cyclooxygenase-\n2 (COX-2). Furthermore, several investigations show that wogonin also attenuates diacylglycerol\nDAG levels in diabetic mice. Since the DAG-PKC pathway is linked with hyperglycemia\nand its complications, Wogonin-mediated DAG-PKC attenuation can help treat hyperglycemia and\nits complications.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929866528666211027113349","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T07:42:58Z","timestamp":1635493378000},"page":"1365-1371","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Wogonin and Alleviation of Hyperglycemia via Inhibition of DAG\nMediated PKC Expression. A Brief Insight"],"prefix":"10.2174","volume":"28","author":[{"given":"Shahzad","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/bj20021626","volume":"370","author":"Newton A.C.","year":"2003","unstructured":"Newton A.C.; Regulation of the ABC kinases by phosphorylation: Protein kinase C as a paradigm. Biochem J 2003,370(Pt 2),361-371","journal-title":"Biochem J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1126\/science.3755547","volume":"233","author":"Parker P.J.","year":"1986","unstructured":"Parker P.J.; Coussens L.; Totty N.; Rhee L.; Young S.; Chen E.; Stabel S.; Waterfield M.D.; Ullrich A.; The complete primary structure of protein kinase C- the major phorbol ester receptor. Science 1986,233(4766),853-859","journal-title":"Science"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1126\/science.3755548","volume":"233","author":"Coussens L.","year":"1986","unstructured":"Coussens L.; Parker P.J.; Rhee L.; Yang-Feng T.L.; Chen E.; Waterfield M.D.; Francke U.; Ullrich A.; Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science 1986,233(4766),859-866","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1152\/physrev.00034.2007","volume":"88","author":"Steinberg S.F.","year":"2008","unstructured":"Steinberg S.F.; Structural basis of protein kinase C isoform function. Physiol Rev 2008,88(4),1341-1378","journal-title":"Physiol Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrd3871","volume":"11","author":"Mochly-Rosen D.","year":"2012","unstructured":"Mochly-Rosen D.; Das K.; Grimes K.V.; Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012,11(12),937-957","journal-title":"Nat Rev Drug Discov"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1046\/j.1523-1755.2000.07705.x","volume":"77","author":"Nishikawa T.","year":"2000","unstructured":"Nishikawa T.; Edelstein D.; Brownlee M.; The missing link: A single unifying mechanism for diabetic complications. Kidney Int Suppl 2000,77,S26-S30","journal-title":"Kidney Int Suppl"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/bj3320281","volume":"332","author":"Mellor H.","year":"1998","unstructured":"Mellor H.; Parker P.J.; The extended protein kinase C superfamily. Biochem J 1998,332(Pt 2),281-292","journal-title":"Biochem J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.bbalip.2006.04.015","volume":"1761","author":"Corbal&#xE1;n-Garc&#xED;a S.","year":"2006","unstructured":"Corbal&#xE1;n-Garc&#xED;a S.; G&#xF3;mez-Fern&#xE1;ndez J.C.; Protein kinase C regulatory domains: the art of decoding many different signals in membranes. Biochim Biophys Acta 2006,1761(7),633-654","journal-title":"Biochim Biophys Acta"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"11233","DOI":"10.1073\/pnas.94.21.11233","volume":"94","author":"Konishi H.","year":"1997","unstructured":"Konishi H.; Tanaka M.; Takemura Y.; Matsuzaki H.; Ono Y.; Kikkawa U.; Nishizuka Y.; Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci USA 1997,94(21),11233-11237","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"Nishikawa T.","year":"2000","unstructured":"Nishikawa T.; Edelstein D.; Du X.L.; Yamagishi S.; Matsumura T.; Kaneda Y.; Yorek M.A.; Beebe D.; Oates P.J.; Hammes H.P.; Giardino I.; Brownlee M.; Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000,404(6779),787-790","journal-title":"Nature"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"11059","DOI":"10.1073\/pnas.89.22.11059","volume":"89","author":"Inoguchi T.","year":"1992","unstructured":"Inoguchi T.; Battan R.; Handler E.; Sportsman J.R.; Heath W.; King G.L.; Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992,89(22),11059-11063","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.272.5262.728","volume":"272","author":"Ishii H.","year":"1996","unstructured":"Ishii H.; Jirousek M.R.; Koya D.; Takagi C.; Xia P.; Clermont A.; Bursell S.E.; Kern T.S.; Ballas L.M.; Heath W.F.; Stramm L.E.; Feener E.P.; King G.L.; Amelioration of vascular dysfunctions in diabetic rats by an oral PKC &#x3B2; inhibitor. Science 1996,272(5262),728-731","journal-title":"Science"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0735-1097(97)00189-7","volume":"30","author":"Celermajer D.S.","year":"1997","unstructured":"Celermajer D.S.; Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol 1997,30(2),325-333","journal-title":"J Am Coll Cardiol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1097\/00004872-199609002-00020","volume":"14","author":"L&#xFC;scher T.F.","year":"1996","unstructured":"L&#xFC;scher T.F.; Noll G.; Endothelial function as an end-point in interventional trials: concepts, methods and current data. J Hypertens 1996,14(2),S111-S1119","journal-title":"J Hypertens"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1167\/iovs.05-0757","volume":"47","author":"Aiello L.P.","year":"2006","unstructured":"Aiello L.P.; Clermont A.; Arora V.; Davis M.D.; Sheetz M.J.; Bursell S.E.; Inhibition of PKC &#x3B2; by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006,47(1),86-92","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1097\/IAE.0b013e3182111669","volume":"31","author":"Aiello L.P.","year":"2011","unstructured":"Aiello L.P.; Vignati L.; Sheetz M.J.; Zhi X.; Girach A.; Davis M.D.; Wolka A.M.; Shahri N.; Milton R.C.; Oral protein kinase c &#x3B2; inhibition using ruboxistaurin: Efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C &#x3B2; Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C &#x3B2; Inhibitor-Diabetic Retinopathy Study 2. Retina 2011,31(10),2084-2094","journal-title":"Retina"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1161\/CIRCULATIONAHA.107.759167","volume":"117","author":"Bates E.","year":"2008","unstructured":"Bates E.; Bode C.; Costa M.; Gibson C.M.; Granger C.; Green C.; Grimes K.; Harrington R.; Huber K.; Kleiman N.; Mochly-Rosen D.; Roe M.; Sadowski Z.; Solomon S.; Widimsky P.; Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008,117(7),886-896","journal-title":"Circulation"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1515\/CCLM.2008.118","volume":"46","author":"Pilz S.","year":"2008","unstructured":"Pilz S.; M&#xE4;rz W.; Free fatty acids as a cardiovascular risk factor. Clin Chem Lab Med 2008,46(4),429-434","journal-title":"Clin Chem Lab Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"767623","DOI":"10.1155\/2008\/767623","volume":"2008","author":"Montecucco F.","year":"2008","unstructured":"Montecucco F.; Steffens S.; Mach F.; Insulin resistance: A proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm 2008,2008,767623","journal-title":"Mediators Inflamm"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1113\/jphysiol.2004.080333","volume":"563","author":"Puljak L.","year":"2005","unstructured":"Puljak L.; Pagliassotti M.J.; Wei Y.; Qadri I.; Parameswara V.; Esser V.; Fitz J.G.; Kilic G.; Inhibition of cellular responses to insulin in a rat liver cell line. A role for PKC in insulin resistance. J Physiol 2005,563(Pt 2),471-482","journal-title":"J Physiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/aps.2011.120","volume":"32","author":"Liu Y.M.","year":"2011","unstructured":"Liu Y.M.; Wang X.; Nawaz A.; Kong Z.H.; Hong Y.; Wang C.H.; Zhang J.J.; Wogonin ameliorates lipotoxicity-induced apoptosis of cultured vascular smooth muscle cells via interfering with DAG-PKC pathway. Acta Pharmacol Sin 2011,32(12),1475-1482","journal-title":"Acta Pharmacol Sin"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s11947-015-1505-0","volume":"8","author":"Phuah E-T.","year":"2015","unstructured":"Phuah E-T.; Review on the current state of diacylglycerol production using enzymatic approach. Food Bioprocess Technol 2015,8(6),1169-1186","journal-title":"Food Bioprocess Technol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.bbamcr.2016.05.006","volume":"1863","author":"Ali E.S.","year":"2016","unstructured":"Ali E.S.; Hua J.; Wilson C.H.; Tallis G.A.; Zhou F.H.; Rychkov G.Y.; Barritt G.J.; The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes. Biochim Biophys Acta 2016,1863(9),2135-2146","journal-title":"Biochim Biophys Acta"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.yjmcc.2010.10.020","volume":"51","author":"Ferreira J.C.","year":"2011","unstructured":"Ferreira J.C.; Brum P.C.; Mochly-Rosen D.; &#x3B2;IIPKC and &#x3B5;PKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 2011,51(4),479-484","journal-title":"J Mol Cell Cardiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cardiores.2006.02.015","volume":"70","author":"Inagaki K.","year":"2006","unstructured":"Inagaki K.; Churchill E.; Mochly-Rosen D.; Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res 2006,70(2),222-230","journal-title":"Cardiovasc Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","volume":"106","author":"Geraldes P.","year":"2010","unstructured":"Geraldes P.; King G.L.; Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010,106(8),1319-1331","journal-title":"Circ Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1161\/res.90.1.5","volume":"90","author":"Gutterman D.D.","year":"2002","unstructured":"Gutterman D.D.; Vascular dysfunction in hyperglycemia: is protein kinase C the culprit? Circulat Res 2002,90,5-7","journal-title":"Circulat Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/01.ATV.0000155325.41507.e0","volume":"25","author":"Rask-Madsen C.","year":"2005","unstructured":"Rask-Madsen C.; King G.L.; Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005,25(3),487-496","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ncpendmet0366","volume":"3","author":"Rask-Madsen C.","year":"2007","unstructured":"Rask-Madsen C.; King G.L.; Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007,3(1),46-56","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1046\/j.1523-1755.1999.00725.x","volume":"56","author":"Kang N.","year":"1999","unstructured":"Kang N.; Alexander G.; Park J.K.; Maasch C.; Buchwalow I.; Luft F.C.; Haller H.; Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int 1999,56(5),1737-1750","journal-title":"Kidney Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1006\/abbi.1993.1281","volume":"303","author":"Taher M.M.","year":"1993","unstructured":"Taher M.M.; Garcia J.G.; Natarajan V.; Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. Arch Biochem Biophys 1993,303(2),260-266","journal-title":"Arch Biochem Biophys"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/BJ20140881","volume":"466","author":"Wilson C.H.","year":"2015","unstructured":"Wilson C.H.; Ali E.S.; Scrimgeour N.; Martin A.M.; Hua J.; Tallis G.A.; Rychkov G.Y.; Barritt G.J.; Steatosis inhibits liver cell store-operated Ca entry and reduces ER Ca through a protein kinase C-dependent mechanism. Biochem J 2015,466(2),379-390","journal-title":"Biochem J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"BSR20171459","DOI":"10.1042\/BSR20171459","volume":"38","author":"Das S.K.","year":"2018","unstructured":"Das S.K.; Yuan Y.F.; Li M.Q.; Specific PKC &#x3B2;II inhibitor: One stone two birds in the treatment of diabetic foot ulcers. Biosci Rep 2018,38(5),BSR20171459","journal-title":"Biosci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3892\/ijmm.2013.1477","volume":"32","author":"Wang F.","year":"2013","unstructured":"Wang F.; Huang D.; Zhu W.; Li S.; Yan M.; Wei M.; Li J.; Selective inhibition of PKC&#x3B2;2 preserves cardiac function after myocardial infarction and is associated with improved angiogenesis of ischemic myocardium in diabetic rats. Int J Mol Med 2013,32(5),1037-1046","journal-title":"Int J Mol Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Nathan D.M.","year":"1993","unstructured":"Nathan D.M.; Genuth S.; Lachin J.; Cleary P.; Crofford O.; Davis M.; Rand L.; Siebert C.; The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993,329(14),977-986","journal-title":"N Engl J Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00280-010-1396-8","volume":"67","author":"Enomoto R.","year":"2011","unstructured":"Enomoto R.; Koshiba C.; Suzuki C.; Lee E.; Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother Pharmacol 2011,67(5),1063-1072","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0378-8741(01)00389-0","volume":"79","author":"Ma S.C.","year":"2002","unstructured":"Ma S.C.; Du J.; But P.P.; Deng X.L.; Zhang Y.W.; Ooi V.E.; Xu H.X.; Lee S.H.; Lee S.F.; Antiviral Chinese medicinal herbs against respiratory syncytial virus. J Ethnopharmacol 2002,79(2),205-211","journal-title":"J Ethnopharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.plefa.2004.04.009","volume":"72","author":"Chi Y.S.","year":"2005","unstructured":"Chi Y.S.; Kim H.P.; Suppression of cyclooxygenase-2 expression of skin fibroblasts by wogonin, a plant flavone from Scutellaria radix. Prostaglandins Leukot Essent Fatty Acids 2005,72(1),59-66","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.bcp.2008.02.023","volume":"75","author":"Lee D.H.","year":"2008","unstructured":"Lee D.H.; Kim C.; Zhang L.; Lee Y.J.; Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol 2008,75(10),2020-2033","journal-title":"Biochem Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2008.09.005","volume":"35","author":"Li-Weber M.","year":"2009","unstructured":"Li-Weber M.; New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 2009,35(1),57-68","journal-title":"Cancer Treat Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0163-7258(02)00298-X","volume":"96","author":"Havsteen B.H.","year":"2002","unstructured":"Havsteen B.H.; The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002,96(2-3),67-202","journal-title":"Pharmacol Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0891-5849(96)00351-6","volume":"22","author":"Cao G.","year":"1997","unstructured":"Cao G.; Sofic E.; Prior R.L.; Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med 1997,22(5),749-760","journal-title":"Free Radic Biol Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3892\/or.2012.1841","volume":"28","author":"He F.","year":"2012","unstructured":"He F.; Wang Q.; Zheng X.L.; Yan J.Q.; Yang L.; Sun H.; Hu L.N.; Lin Y.; Wang X.; Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species. Oncol Rep 2012,28(2),601-605","journal-title":"Oncol Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1349-7006.2011.01874.x","volume":"102","author":"Yang L.","year":"2011","unstructured":"Yang L.; Zheng X.L.; Sun H.; Zhong Y.J.; Wang Q.; He H.N.; Shi X.W.; Zhou B.; Li J.K.; Lin Y.; Zhang L.; Wang X.; Catalase suppression-mediated H(2)O(2) accumulation in cancer cells by wogonin effectively blocks tumor necrosis factor-induced NF-&#x3BA;B activation and sensitizes apoptosis. Cancer Sci 2011,102(4),870-876","journal-title":"Cancer Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/mc.22093","volume":"54","author":"Song X.","year":"2015","unstructured":"Song X.; Zhou Y.; Zhou M.; Huang Y.; Li Z.; You Q.; Lu N.; Guo Q.; Wogonin influences vascular permeability via Wnt\/&#x3B2;-catenin pathway. Mol Carcinog 2015,54(7),501-512","journal-title":"Mol Carcinog"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.2174\/1381612825666190708173108","volume":"25","author":"Khan S.","year":"2019","unstructured":"Khan S.; Kamal M.A.; Can wogonin be used in controlling diabetic cardiomyopathy? Curr Pharm Des 2019,25(19),2171-2177","journal-title":"Curr Pharm Des"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.clnu.2013.03.013","volume":"33","author":"Bak E.J.","year":"2014","unstructured":"Bak E.J.; Kim J.; Choi Y.H.; Kim J.H.; Lee D.E.; Woo G.H.; Cha J.H.; Yoo Y.J.; Wogonin ameliorates hyperglycemia and dyslipidemia via PPAR&#x3B1; activation in db\/db mice. Clin Nutr 2014,33(1),156-163","journal-title":"Clin Nutr"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10557-008-6144-5","volume":"23","author":"Mehta N.N.","year":"2009","unstructured":"Mehta N.N.; Sheetz M.; Price K.; Comiskey L.; Amrutia S.; Iqbal N.; Mohler E.R.; Reilly M.P.; Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther 2009,23(1),17-24","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","volume":"28","author":"Tuttle K.R.","year":"2005","unstructured":"Tuttle K.R.; Bakris G.L.; Toto R.D.; McGill J.B.; Hu K.; Anderson P.W.; The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005,28(11),2686-2690","journal-title":"Diabetes Care"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2337\/diab.43.11.1372","volume":"43","author":"Kunisaki M.","year":"1994","unstructured":"Kunisaki M.; Bursell S.E.; Umeda F.; Nawata H.; King G.L.; Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994,43(11),1372-1377","journal-title":"Diabetes"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1046\/j.0742-3071.2001.00638.x","volume":"18","author":"Way K.J.","year":"2001","unstructured":"Way K.J.; Katai N.; King G.L.; Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001,18(12),945-959","journal-title":"Diabet Med"},{"key":"ref=52","first-page":"E239","volume":"269","author":"Kunisaki M.","year":"1995","unstructured":"Kunisaki M.; Bursell S.E.; Clermont A.C.; Ishii H.; Ballas L.M.; Jirousek M.R.; Umeda F.; Nawata H.; King G.L.; Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 1995,269(2 Pt 1),E239-E246","journal-title":"Am J Physiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1161\/01.ATV.21.6.937","volume":"21","author":"Yasunari K.","year":"2001","unstructured":"Yasunari K.; Maeda K.; Minami M.; Yoshikawa J.; HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001,21(6),937-942","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/197423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197423\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/197423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T11:35:39Z","timestamp":1645961739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197423\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929866528666211027113349","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}